We studied 43 patients with newly diagnosed, untreated, stage D2 prost
atic carcinoma, and correlated the initial performance status, hemoglo
bin, prostate specific antigen levels, tumor Gleason grade, extent of
disease on the bone scan, and erythrocyte spermidine and spermine leve
ls with progression. Three patients died of unrelated causes and were
excluded from the study, 16 remained in remission with a mean 28 +/- 1
1 months of followup and 24 had progression (18, or 75%, of whom died
of the cancer) with a mean 12 +/- 9 months of followup (p < 0.05 for f
ollowup) after initiation of hormonal therapy. Pretreatment performanc
e status, hemoglobin, and erythrocyte spermidine and spermine levels w
ere correlated with progression, hemoglobin and spermine being the mos
t significant independent variables (p = 0.006 and p = 0.001, respecti
vely). Concerning cause-specific survival, only hemoglobin and spermin
e erythrocyte levels were significant independent variables (p = 0.02
and p = 0.0025, respectively). If confirmed, polyamine erythrocyte lev
els obtained by a simple blood sample could discriminate at diagnosis
patients with a high risk of rapid hormonal relapse who may benefit fr
om a more aggressive primary management.